ERBB2 and cancer: Interestingly, amplification ofoncogenes such as n-MYC in neuroblastoma(Brodeur etal., 1984)or HER2/NEU amplification in breast carcinoma(Press et al., 1997) was shown to predict poor prognosisin cancer patients.